The Role of PARP Inhibitors in Breast Cancer
WebcastFaculty
OVERVIEW
The Role of PARP Inhibitors in Breast Cancer is organized by PRIME Oncology and will be held during Oct 19, 2017 - Oct 19, 2018.
The target audience for this medical event is designed for surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with breast cancer.
Course Description :
This Expert Review features an expert discussion and downloadable slides focusing on the role of PARP inhibitors in breast cancer, including mechanism of action, emerging clinical data and ongoing trials in the early and metastatic settings, and patient selection for treatment.
Topics:
• PARP inhibitors mechanism of action
• Rationale for PARP inhibition in breast cancer
• Patient selection
• PARP inhibitors in metastatic breast cancer
• PARP inhibitors in early breast cancer
• Clinical implications
Conference Objectives are :
• Describe the impact of BRCA 1/2 testing on clinical outcomes for patients with breast cancer
• Assess recent and ongoing clinical trial data of PARP inhibitors in patients with breast cancer
• Select optimal treatment options, based on current treatment guidelines and emerging clinical trial data, for patients with triple-negative and BRCA-mutated breast cancer
Additional details will be posted as soon as they are available.
The target audience for this medical event is designed for surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with breast cancer.
Course Description :
This Expert Review features an expert discussion and downloadable slides focusing on the role of PARP inhibitors in breast cancer, including mechanism of action, emerging clinical data and ongoing trials in the early and metastatic settings, and patient selection for treatment.
Topics:
• PARP inhibitors mechanism of action
• Rationale for PARP inhibition in breast cancer
• Patient selection
• PARP inhibitors in metastatic breast cancer
• PARP inhibitors in early breast cancer
• Clinical implications
Conference Objectives are :
• Describe the impact of BRCA 1/2 testing on clinical outcomes for patients with breast cancer
• Assess recent and ongoing clinical trial data of PARP inhibitors in patients with breast cancer
• Select optimal treatment options, based on current treatment guidelines and emerging clinical trial data, for patients with triple-negative and BRCA-mutated breast cancer
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links